Blood test study for women with advanced breast cancer
Part of Cancer, Skin clinical trials.
This study looks at a blood test that measures certain markers on cancer cells (CTCs) and genetic material in the blood (cfDNA/RNA) in women with metastatic breast cancer. It aims to better understand the cancer and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that has spread to other parts of the body or cannot be removed by surgery.
- Your cancer type is either: hormone receptor-positive and HER2-negative, triple-negative, or HER2-positive (with certain treatment history).
- You are about to start your first treatment for metastatic disease (or later line for HER2-positive).
- Your doctor has ordered specific blood tests (CTC HER2, ER, PD-L1, and cfDNA/RNA) as part of your routine care.
- You are 18 years or older.
- You are not pregnant and can provide blood samples.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial studies using a blood test to monitor how treatment is working in people with metastatic breast cancer. It may help your care team track your cancer over time with a simpler test.
This Phase 2 study uses a blood test that looks for “circulating tumor DNA” to help decide if standard chemotherapy should be changed. It aims to see whether this approach improves how well treatment works for certain metastatic (stage IV) breast cancers.
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
This trial uses a simple blood test to look for two specific gene changes (ESR-1 and gBRCA) in people with hormone receptor-positive, HER2-negative breast cancer that has spread. It aims to detect these mutations earlier and help guide future treatment decisions.
This trial tests whether a blood test (ctDNA) can help doctors monitor how well chemotherapy before surgery is working in women with HER2-positive breast cancer. It aims to see if changes in the blood can predict treatment success.
Hear when a new Metastatic Breast Cancer (MBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.